Supplemental 2

Supplemental Table 1. Primers sequences used for the studies

	Sequences
Wnt3	F: 5'- AGCCTGGGTATAGCTGCATGT -3'
	R: 5'- AGCCTGGGTATAGCTGCATGT -3'
Wnt4	F: 5'- GTCAGGCTCCTGTGAGGTAAAG- 3'
	R: 5'- GTACACCAGGTCCTCATCTGTG- 3'
Wnt6	F: 5'- GAGAGTGCCAGTTCCAGTTCC -3'
	R: 5'- ATAGAACAGGCCTGCGTGAC -3'
Wnt11	F: 5'- CTTCGCTGTACCGTCTACTGG -3'
	R: 5'- ACAGGTATCGGGTCTTGAGGT-3'
FZD1	F: 5'-CTTCTTGTCCGGCTGTTACAC-3'
	R: 5'-CTGGCCATGCTGAAGAAGTAG-3'
FZD4	F: 5'- ATGAACTGACTGGCTTGTGCT-3'
	R: 5'- TTGTCTGTCTTTGTCCCATCC-3'
FZD5	F: 5'-TCTATGTACACGCCCATCTGTC-3'

	R: 5’-GGTTGTAATCCATGCAGAGGAC-3’
WIF1	F: 5’-ATTCTGAAGGCAACACCATTCT-3’
	R: 5’-TTCATACATCGTGGGGTACAAA-3’
CTNNB1 (β-catenin)	F: 5’-GGGACACAGCAGCAATTTGT-3’
	R: 5’-CAGCTGCACAAACAATGGAA-3’
AXIN1	F: 5’-TGCCGACCTTAAATGAAGATG-3’
	R: 5’-CTTCGCTGTACCGTCTACTGG-3’
AXIN2	F: 5’-AGATCCAGTCGGTGATGGAG-3’
	R: 5’-CTTCATTCAAGGTGGGGAGA-3’
TCF1	F: 5’-AGGAGATGAGAGCCAAGGTCA-3’
	R: 5’-AGCCTGGGTATAGCTGCATGT-3’
Twist	F: 5’-AGTCCGCAGTCTTACGAGGAG-3’
	R: 5’-TTGAGGGTCTGAATCTTGCTC-3’
SLUG	F: 5’-AGAGCATTTGCAGACAGGTCA-3’
	R: 5’-AGCAGCCAGATTCCTCATGTT-3’

Vimentin	F: 5’-TGGCACGTCTTGACCTTGAA-3’ R: 5’-GGTCATCGTGATGCTGAGAA-3’
CDH1 (E-cadherin)	F: 5’-TTTGAGGCCAAGCAGCAGTA-3’ R: 5’-ATGGGGGCTTCATTCACATC-3’
CDH2 (N-cadherin)	F: 5’-GGGTAATCCTCCCAAATCAAA-3’ R: 5’-TCCATACCACAAACATCAGCA-3’
Nanog	F: 5’-GAACTCTCCAACATCCTGAACC-3’ R: 5’-TCCCTGGTGGTAGGAAGAGTAA-3’
PPARD	F: 5’-GTGTGGAAGCAGTTGGTGAA-3’ R: 5’-TGCACGCCATACTTGAGAAG-3’
Survivin	F: 5’- ACTTGGCCCAGTGTTTCTTCT-3’ R: 5’-TCTTGGCTCTTTCTCTGTCCA-3’
c-Myc	F: 5’-CCTCCACTCGGAAGGACTATC-3’ R: 5’-AAGCTCCGTTTTAGCTCGTTC-3’
c-Jun	F: 5’-GAAGGAGGAGCCTCAGACAGT-3’ R: 5’-CGATTCTCTCCAGCTTCCTTT-3’

EGFR	F: 5’-CGAAACGTGCTACTCAAGTCAC-3’ R: 5’-CCCAAAGTGGATACTCTCAAGG-3’
18S	F: 5’-GATCCATTGGAGGGCAAGTC-3’ R: 5’-TCCCAAGATCCAACTACGAG-3’